Literature DB >> 17309665

Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience.

W K Huh1, J M Straughn, A Mariani, K C Podratz, L J Havrilesky, A Alvarez-Secord, M A Gold, D S McMeekin, S Modesitt, A L Cooper, M A Powell, D G Mutch, S Nag, R D Alvarez, D E Cohn.   

Abstract

The objective of this study was to evaluate the treatment outcomes and risk factors of women with surgical stage I endometrial adenocarcinoma who were initially treated with surgery alone and subsequently developed isolated vaginal recurrences. Patients with surgical stage I endometrial adenocarcinoma diagnosed from 1975 to 2002 were identified from tumor registry databases at seven institutions. All patients were treated with surgery alone including a total hysterectomy, bilateral salpingo-oophorectomy, pelvic (+/- para-aortic) lymph node dissection, and peritoneal cytology and did not receive postoperative radiation therapy. Vaginal recurrences were documented histologically. Metastatic disease in the chest and abdomen was excluded by radiologic studies. Overall survival was calculated by the Kaplan-Meier method. Sixty-nine women with surgical stage I endometrial cancer with isolated vaginal recurrences were identified. Of the 69 patients, 10 (15%) were diagnosed with stage IA disease, 43 (62%) were diagnosed with stage IB disease, and 16 (23%) were diagnosed with stage IC disease. Patients diagnosed with grade 1 disease were 22 (32%), grade 2 disease were 26 (38%), and grade 3 disease were 21 (30%). Among women, 81% with isolated vaginal recurrences were salvaged with radiation therapy. The mean time to recurrence was 24 months, and the mean follow-up was 63 months. Among women, 18% died from subsequent recurrent disease. The 5-year overall survival was 75%. The majority of isolated vaginal recurrences in women with surgical stage I endometrial cancer can be successfully salvaged with radiation therapy, further questioning the role of adjuvant therapy for patients with uterine-confined endometrial cancer at the time of initial diagnosis.

Entities:  

Mesh:

Year:  2007        PMID: 17309665     DOI: 10.1111/j.1525-1438.2007.00858.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  12 in total

1.  Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.

Authors:  Casey M Cosgrove; David E Cohn; Heather Hampel; Wendy L Frankel; Dan Jones; Joseph P McElroy; Adrian A Suarez; Weiqiang Zhao; Wei Chen; Ritu Salani; Larry J Copeland; David M O'Malley; Jeffrey M Fowler; Ahmet Yilmaz; Alexis S Chassen; Rachel Pearlman; Paul J Goodfellow; Floor J Backes
Journal:  Gynecol Oncol       Date:  2017-07-11       Impact factor: 5.482

2.  Outcomes After Salvage Radiation Therapy for Recurrent Endometrial Cancer in Patients With No Prior Adjuvant Therapy: An Institutional Review.

Authors:  Jessica D Arden; Morgan F Gruner; Charles C Vu; Kimberly Marvin; Hong Ye; Sirisha R Nandalur; Zaid Al-Wahab; Jill Gadzinski; Joseph Anthony Rakowski; Jayson Field; Barry Rosen; Maha Saada Jawad
Journal:  Adv Radiat Oncol       Date:  2020-09-09

3.  Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma.

Authors:  Melody J Xu; Christina Chu; Stephen Rubin; Lilie L Lin
Journal:  Am J Clin Oncol       Date:  2017-12       Impact factor: 2.339

4.  The utility and management of vaginal cytology after treatment for endometrial cancer.

Authors:  Akiva P Novetsky; Lindsay M Kuroki; L Stewart Massad; Andrea R Hagemann; Premal H Thaker; Matthew A Powell; David G Mutch; Israel Zighelboim
Journal:  Obstet Gynecol       Date:  2013-01       Impact factor: 7.661

5.  Vaginal vault recurrences of endometrial cancer in non-irradiated patients - Radiotherapy or surgery.

Authors:  Hordur Alexander Hardarson; Lene Nyhøj Heidemann; René dePont Christensen; Ole Mogensen; Kirsten M Jochumsen
Journal:  Gynecol Oncol Rep       Date:  2015-01-16

Review 6.  Brachytherapy for malignancies of the vagina in the 3D era.

Authors:  Scott M Glaser; Sushil Beriwal
Journal:  J Contemp Brachytherapy       Date:  2015-09-14

7.  Clinical outcomes of stage I endometrial carcinoma patients treated with surgery alone: Siriraj Hospital experiences.

Authors:  Suwanit Therasakvichya; Sompop Kuljarusnont; Janjira Petsuksiri; Pattama Chaopotong; Vuthinun Achariyapota; Pisutt Srichaikul; Atthapon Jaishuen
Journal:  J Gynecol Oncol       Date:  2016-05-16       Impact factor: 4.401

8.  Survival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy.

Authors:  Shaakir Hasan; Anthony Ricco; Kaylette Jenkins; Rachelle Lanciano; Alexandra Hanlon; John Lamond; Jun Yang; Jing Feng; Michael Good; Joel Noumoff; Luther Brady
Journal:  Front Oncol       Date:  2016-11-22       Impact factor: 6.244

9.  High-dose rate brachytherapy (HDRB) for primary or recurrent cancer in the vagina.

Authors:  Sushil Beriwal; Dwight E Heron; Robert Mogus; Robert P Edwards; Joseph L Kelley; Paniti Sukumvanich
Journal:  Radiat Oncol       Date:  2008-02-13       Impact factor: 3.481

10.  Contemporary clinical management of endometrial cancer.

Authors:  Helen E Dinkelspiel; Jason D Wright; Sharyn N Lewin; Thomas J Herzog
Journal:  Obstet Gynecol Int       Date:  2013-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.